Presentation Preview: Contextualizing Clinical Success of Enhertu Combination to Secure First- Line Approval in HER2+ Metastatic Breast Cancer
- Envisioning potential for Enhertu to move from advanced to early oncology settings
- Delving into the clinical data and first-line approval of Enhertu combination therapy in HER2+ metastatic breast cancer
- Laying out rationale-driven research to identify combination partners complimentary to Enhertu mechanism